Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease
- PMID: 22272610
- PMCID: PMC3348519
- DOI: 10.2174/156720512800492567
Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease
Abstract
More than a third of Alzheimer's disease (AD) patients show nigrostriatal pathway disturbances, resulting in akinesia (inability to initiate movement) and bradykinesia (slowness of movement). The high prevalence of this dysfunction of dopaminergic neuron in the nigrostriatal pathway in AD suggests that the risk factors for AD appear also significant risk factors for substantia nigra pars compacta (SNpc) lesions. Previously, we have demonstrated that allopregnanolone (APα) promotes neurogenesis and improves the cognitive function in a triple transgenic mouse model of AD (3xTgAD). In this study, we sought to exam 1) the SNpc lesions in 3xTgAD mice and 2) the impact of APα on promoting the regeneration of new dopaminergic neurons in SNpc of the 3xTgAD mice. The number of Nissl-stained total neurons, tyrosine hydroxylase (TH) positive neurons, and BrdU/TH double positive newly formed neurons were analyzed with unbiased stereology. In the SNpc of 3xTgAD mice, TH positive neurons was 47+- 18 % (p = 0.007), total neurons was 62 +-11.6 % (p = 0.016), of those in the SNpc of non-Tg mice, respectively. APα treatment increased the TH positive neurons in the SNpc of 3xTgAD mice to 93.2 +- 18.5 (p = 0.021 vs. 3xTgAD vehicle) and the total neurons to 84.9+- 6.6 (p = 0.046 vs. 3xTgAD vehicle) of non-Tg mice. These findings indicate that there is a loss of neurons, specifically the TH positive neurons in SNpc of 3xTgAD mice, and that APα reverses the lesion in SNpc of 3xTgAD by increasing the formation of new TH neurons.
Figures


Similar articles
-
Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice.Neuroscience. 2015 Apr 2;290:214-26. doi: 10.1016/j.neuroscience.2015.01.019. Epub 2015 Jan 28. Neuroscience. 2015. PMID: 25637494
-
Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease.Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6498-503. doi: 10.1073/pnas.1001422107. Epub 2010 Mar 15. Proc Natl Acad Sci U S A. 2010. PMID: 20231471 Free PMC article.
-
Nmnat1 Modulates Mitochondrial Oxidative Stress by Inhibiting Caspase-3 Signaling in Alzheimer's Disease.J Mol Neurosci. 2021 Jul;71(7):1467-1472. doi: 10.1007/s12031-020-01781-8. Epub 2021 Jan 14. J Mol Neurosci. 2021. PMID: 33447901
-
Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent.Curr Alzheimer Res. 2007 Dec;4(5):510-7. doi: 10.2174/156720507783018262. Curr Alzheimer Res. 2007. PMID: 18220513 Free PMC article. Review.
-
Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease.Curr Alzheimer Res. 2006 Feb;3(1):11-7. doi: 10.2174/156720506775697160. Curr Alzheimer Res. 2006. PMID: 16472197 Review.
Cited by
-
Allopregnanolone pleiotropic action in neurons and astrocytes: calcium signaling as a unifying mechanism.Front Endocrinol (Lausanne). 2023 Dec 22;14:1286931. doi: 10.3389/fendo.2023.1286931. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38189047 Free PMC article.
-
Mitochondria modulatory effects of new TSPO ligands in a cellular model of tauopathies.J Neuroendocrinol. 2020 Jan;32(1):e12796. doi: 10.1111/jne.12796. Epub 2019 Oct 13. J Neuroendocrinol. 2020. PMID: 31536662 Free PMC article.
-
Endogenous versus exogenous cell replacement for Parkinson's disease: where are we at and where are we going?Neural Regen Res. 2022 Dec;17(12):2637-2642. doi: 10.4103/1673-5374.336137. Neural Regen Res. 2022. PMID: 35662194 Free PMC article. Review.
-
Allopregnanolone Improves Locomotor Activity and Arousal in the Aged CGG Knock-in Mouse Model of Fragile X-Associated Tremor/Ataxia Syndrome.Front Neurosci. 2021 Dec 3;15:752973. doi: 10.3389/fnins.2021.752973. eCollection 2021. Front Neurosci. 2021. PMID: 34924931 Free PMC article.
-
Neurosteroids as regenerative agents in the brain: therapeutic implications.Nat Rev Endocrinol. 2013 Apr;9(4):241-50. doi: 10.1038/nrendo.2013.31. Epub 2013 Feb 26. Nat Rev Endocrinol. 2013. PMID: 23438839 Free PMC article. Review.
References
-
- Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology. 1985;35:453–461. - PubMed
-
- Jimenez-Escrig A, Rabano A, Guerrero C, Simon J, Barquero MS, Guell I, et al. New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism. Eur J Neurol. 2004;11:663–669. - PubMed
-
- Jellinger KA. Alpha-synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution--a pilot study. Acta Neuropathol. 2003;106:191–201. - PubMed
-
- Verny M, Duyckaerts C. Dementia with Lewy bodies. Ann Med Interne (Paris) 1998;149:209–215. - PubMed
-
- Gomez-Tortosa E, Ingraham AO, Irizarry MC, Hyman BT. Dementia with Lewy bodies. J Am Geriatr Soc. 1998;46:1449–1458. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous